Aránzazu Manzano

2.8k total citations · 1 hit paper
58 papers, 1.1k citations indexed

About

Aránzazu Manzano is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Reproductive Medicine. According to data from OpenAlex, Aránzazu Manzano has authored 58 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Oncology, 18 papers in Pulmonary and Respiratory Medicine and 12 papers in Reproductive Medicine. Recurrent topics in Aránzazu Manzano's work include Ovarian cancer diagnosis and treatment (12 papers), HER2/EGFR in Cancer Research (8 papers) and Cancer Immunotherapy and Biomarkers (8 papers). Aránzazu Manzano is often cited by papers focused on Ovarian cancer diagnosis and treatment (12 papers), HER2/EGFR in Cancer Research (8 papers) and Cancer Immunotherapy and Biomarkers (8 papers). Aránzazu Manzano collaborates with scholars based in Spain, United States and Hungary. Aránzazu Manzano's co-authors include Pedro Pérez‐Segura, Antonio González-Martı́n, Antonio Casado, Gloria Marquina, Do‐Youn Oh, Iwona Ługowska, Yan Ma, Funda Meric‐Bernstam, Soham D. Puvvada and Salvatore Siena and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Scientific Reports.

In The Last Decade

Aránzazu Manzano

48 papers receiving 1.1k citations

Hit Papers

Efficacy and Safety of Trastuzumab Deruxtecan in Patients... 2023 2026 2024 2025 2023 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial
    2023 432 citations Funda Meric‐Bernstam, Vicky Makker et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Aránzazu Manzano Spain 16 571 308 240 216 200 58 1.1k
Véronique D’Hondt France 21 781 1.4× 335 1.1× 298 1.2× 144 0.7× 241 1.2× 83 1.3k
Anne‐Claire Hardy‐Bessard France 16 640 1.1× 206 0.7× 152 0.6× 125 0.6× 230 1.1× 59 961
Catherine Shannon Australia 20 704 1.2× 286 0.9× 148 0.6× 191 0.9× 285 1.4× 48 1.2k
Jurjees Hasan United Kingdom 15 371 0.6× 197 0.6× 326 1.4× 150 0.7× 185 0.9× 53 919
Alfonso Sánchez‐Muñoz Spain 19 537 0.9× 186 0.6× 234 1.0× 173 0.8× 361 1.8× 56 1.0k
Corinne Doll Canada 20 401 0.7× 207 0.7× 183 0.8× 388 1.8× 161 0.8× 70 1.1k
G. Schubert-Fritschle Germany 16 485 0.8× 217 0.7× 164 0.7× 168 0.8× 185 0.9× 58 847
Ida Paris Italy 16 370 0.6× 189 0.6× 210 0.9× 206 1.0× 167 0.8× 72 870
Naveen Faridi Pakistan 24 570 1.0× 265 0.9× 185 0.8× 291 1.3× 345 1.7× 85 1.4k
George Zarkavelis Greece 15 458 0.8× 170 0.6× 169 0.7× 126 0.6× 158 0.8× 52 813

Countries citing papers authored by Aránzazu Manzano

Since Specialization
Citations

This map shows the geographic impact of Aránzazu Manzano's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aránzazu Manzano with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aránzazu Manzano more than expected).

Fields of papers citing papers by Aránzazu Manzano

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aránzazu Manzano. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aránzazu Manzano. The network helps show where Aránzazu Manzano may publish in the future.

Co-authorship network of co-authors of Aránzazu Manzano

This figure shows the co-authorship network connecting the top 25 collaborators of Aránzazu Manzano. A scholar is included among the top collaborators of Aránzazu Manzano based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aránzazu Manzano. Aránzazu Manzano is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Oaknin, Ana, Jung‐Yun Lee, Vicky Makker, et al.. (2025). Summary of Research: Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02. Advances in Therapy. 42(5). 2015–2018. 2 indexed citations
2.
Hernández, Raquel, Ana Fernández Montés, Alejandro Gallego, et al.. (2024). Prospective study of predictors for anxiety, depression, and somatization in a sample of 1807 cancer patients. Scientific Reports. 14(1). 3188–3188. 12 indexed citations
3.
Moreno, Irene, Cristina Nieto‐Jiménez, Bernard Doger, et al.. (2024). Genomic and Immunologic Correlates in Prostate Cancer with High Expression of KLK2. International Journal of Molecular Sciences. 25(4). 2222–2222. 3 indexed citations
4.
5.
Oaknin, Ana, Jung‐Yun Lee, Vicky Makker, et al.. (2024). Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02. Advances in Therapy. 41(11). 4125–4139. 9 indexed citations
6.
Tavira, Beatriz, Luís Manso, Ana Santaballa, et al.. (2023). Analysis of Tumor Microenvironment Changes after Neoadjuvant Chemotherapy with or without Bevacizumab in Advanced Ovarian Cancer (GEICO-89T/MINOVA Study). Clinical Cancer Research. 30(1). 176–186. 6 indexed citations
7.
Meric‐Bernstam, Funda, Vicky Makker, Ana Oaknin, et al.. (2023). LBA34 Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) with HER2-expressing solid tumors: Primary analysis from the DESTINY-PanTumor02 (DP-02) study. Annals of Oncology. 34. S1273–S1274. 3 indexed citations
8.
Meric‐Bernstam, Funda, Vicky Makker, Ana Oaknin, et al.. (2023). Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial. Journal of Clinical Oncology. 42(1). 47–58. 432 indexed citations breakdown →
9.
Fernández-Hinojal, G., Aránzazu Manzano, Pedro Pérez‐Segura, et al.. (2023). Prognostic value of human leukocyte antigen G expression in solid tumors: a systematic review and meta-analysis. Frontiers in Immunology. 14. 1165813–1165813. 11 indexed citations
10.
Baliu‐Piqué, Mariona, Aránzazu Manzano, Cristina Sáiz-Ladera, et al.. (2021). In silico transcriptomic mapping of integrins and immune activation in Basal-like and HER2+ breast cancer. Cellular Oncology. 44(3). 569–580. 17 indexed citations
11.
Noblejas‐López, María del Mar, Jesús Fuentes‐Antrás, G. Fernández-Hinojal, et al.. (2021). Genomic Mapping of Splicing-Related Genes Identify Amplifications in LSM1, CLNS1A, and ILF2 in Luminal Breast Cancer. Cancers. 13(16). 4118–4118. 8 indexed citations
12.
Sáiz-Ladera, Cristina, Mariona Baliu‐Piqué, Francisco J. Cimas, et al.. (2021). Transcriptomic Correlates of Immunologic Activation in Head and Neck and Cervical Cancer. Frontiers in Oncology. 11. 714550–714550. 6 indexed citations
13.
Pérez‐Peña, Javier, János Tibor Fekete, Vanesa García‐Barberán, et al.. (2019). A transcriptomic immunologic signature predicts favorable outcome in neoadjuvant chemotherapy treated triple negative breast tumours. Annals of Oncology. 30. v509–v509. 1 indexed citations
14.
Pérez‐Peña, Javier, János Tibor Fekete, Mariona Baliu‐Piqué, et al.. (2019). A Transcriptomic Immunologic Signature Predicts Favorable Outcome in Neoadjuvant Chemotherapy Treated Triple Negative Breast Tumors. Frontiers in Immunology. 10. 2802–2802. 24 indexed citations
15.
Zeybek, Burak, Aránzazu Manzano, Anna Bianchi, et al.. (2019). Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan.. Journal of Clinical Oncology. 37(15_suppl). e17028–e17028. 5 indexed citations
16.
Marquina, Gloria, Aránzazu Manzano, & Antonio Casado. (2018). Targeted Agents in Cervical Cancer: Beyond Bevacizumab. Current Oncology Reports. 20(5). 40–40. 83 indexed citations
17.
18.
Puente, Javier, et al.. (2014). Renal cell cancer metastases to esophagus and stomach successfully treated with radiotherapy and pazopanib. Anti-Cancer Drugs. 26(1). 112–116. 13 indexed citations
19.
Zugazagoitia, Jon, Javier Puente, J.L. González-Larriba, et al.. (2013). Erlotinib versus Pemetrexed for Pretreated Non-Squamous Non-Small Cell Lung Cancer Patients in Clinical Practice. Oncology. 84(5). 255–264. 6 indexed citations
20.
Zugazagoitia, Jon, Aránzazu Manzano, Javier Sastre, et al.. (2012). Sorafenib for non-selected patient population with advanced hepatocellular carcinoma: efficacy and safety data according to liver function. Clinical & Translational Oncology. 15(2). 146–153. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Véronique D’Hondt Breakdown of academic impact, for papers by Anne‐Claire Hardy‐Bessard Breakdown of academic impact, for papers by Catherine Shannon Breakdown of academic impact, for papers by Jurjees Hasan Breakdown of academic impact, for papers by Alfonso Sánchez‐Muñoz Breakdown of academic impact, for papers by Corinne Doll Breakdown of academic impact, for papers by G. Schubert-Fritschle Breakdown of academic impact, for papers by Ida Paris Breakdown of academic impact, for papers by Naveen Faridi Breakdown of academic impact, for papers by George Zarkavelis
Rankless by CCL
2026